Pancreatic cancer: Disrupting the chemokine axis in PDAC
暂无分享，去创建一个
[1] Kathryn J Fowler,et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. , 2016, The Lancet. Oncology.
[2] M. Hidalgo,et al. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies , 2015, Nature Reviews Clinical Oncology.